semaglutide risk of cancer GLP-1 drugs and cancer: the headline is exciting. The full picture is more nuanced. New research from @ascocancer 2026 shows patients on GLP-1 medications like were up to 50% less likely semaglutide cancer cases Long-term risk

The 0.25 mg dose is not therapeutic on its own it only builds tolerance

Trapp S, Stanford SC

Further investigation of differential gene expression in -1 cells revealed that the most highly upregulated transcripts in response to liraglutide treatment were INS and IAPP (Figure 4, A and B, and Supplemental Figure 4A

By enhancing feelings of fullness and reducing hunger, semaglutide helps you make healthier eating choices and maintain a caloric deficit essential for weight loss

Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis

At least for these two doctors, the trial period appears to be over